Interleukin-2-targeted fusion toxin with diphtheria toxin data

SRGN (Hopkinton, Mass.) announced that 12 of 32 patients in a Phase I/II trial have had a reduction in tumor burden of 50 to 100 percent, with five patients experiencing complete clearing of the disease.

As presented at the International Conference on Monoclonal Antibody Immunoconjugates for Cancer Research in San Diego, the toxin was delivered in 15-minute intravenous infusions given daily for five days, every three weeks, for up to six courses. ...